<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543620</url>
  </required_header>
  <id_info>
    <org_study_id>Kidney Safety - Aminoglycoside</org_study_id>
    <nct_id>NCT01543620</nct_id>
  </id_info>
  <brief_title>Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis</brief_title>
  <official_title>Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for the National Institutes of Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johnson &amp; Johnson</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Critical Path Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Predictive Safety Testing Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation for the National Institutes of Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project is designed to test new biomarkers that are more sensitive than the current
      standard in detecting injury to the proximal kidney tubule and will establish better criteria
      for when kidney safety concerns may halt further testing of a drug in humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this clinical study is to advance the acceptance of new biomarkers designed to
      detect drug-induced kidney injury in clinical trials.

      The Kidney Safety Project is being conducted at four major medical centers:

        -  University of Southern California

        -  University of Minnesota

        -  MD Anderson Cancer Center

        -  Dana-Farber Cancer Institute.

      Blood and urine samples will be collected from patients undergoing treatment with either
      cisplatin or aminoglycosides, which are two different drugs known to cause injuries to the
      proximal tubule of the kidney. Aminoglycosides are a common antibiotic drug taken by patients
      with cystic fibrosis. Cisplatin is a common chemotherapy drug taken by patients with head and
      neck cancer.

      The Aminoglycoside Study of the Kidney Safety Project is being conducted at the University of
      Southern California and the University of Minnesota and aims to evaluate aminoglycoside
      induced acute kidney injury in patients with cystic fibrosis.

      The companion study, the Cisplatin Study of the Kidney Safety Project, is being conducted at
      the MD Anderson Cancer Center and the Dana-Farber Cancer Institute and aims to evaluate
      cisplatin induced acute kidney injury in patients with head and neck cancer.

      The data from the Kidney Safety Project, from both the Aminoglycoside Study and the Cisplatin
      Study, will be combined for determination of the best biomarkers for predicting drug-induced
      acute kidney injury.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Patients with cystic fibrosis treated with aminoglycosides</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with cystic fibrosis not treated with aminoglycosides</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      urine and blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        cystic fibrosis patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Males and females â‰¥ 18 years of age.

          2. Documentation of CF diagnosis as evidenced by one or more clinical features consistent
             with the CF phenotype and one or more of the following criteria:

               -  Sweat chloride greater than or equal to 60 mEq/L by quantitative pilocarpine
                  iontophoresis test.

               -  Two well-characterized mutations in the cystic fibrosis transmembrane conductance
                  regulator (CFTR) gene; or

               -  Abnormal nasal potential difference.

          3. Hospitalized and initiated on systemic antibiotic therapy for treatment of an acute
             pulmonary exacerbation.

          4. Willingness and ability to comply with study procedures and study restrictions.

          5. Ability to provide written informed consent.

        Exclusion criteria:

          1. Chronic kidney disease defined by microalbuminuria (&gt; 30 mcg/mg creatinine) or eGFR &lt;
             60 mL/min/1.73m2.

          2. Receiving medications known to alter the tubular secretion of creatinine (e.g.
             trimethoprim, cimetidine).

          3. Hospitalized for treatment of an acute pulmonary exacerbation or received intravenous
             aminoglycoside antibiotics within 3-months of study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Beringer, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joanne Billings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irene Nunes, OD, PhD</last_name>
    <phone>(732) 594-1137</phone>
    <email>irene_nunes@merck.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica Ratay, MS</last_name>
    <phone>(301) 435-4038</phone>
    <email>jratay@fnih.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator1</last_name>
    </contact>
    <contact_backup>
      <last_name>Research Coordinator2</last_name>
    </contact_backup>
    <investigator>
      <last_name>Paul Beringer, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota - Cystic Fibrosis Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator1</last_name>
    </contact>
    <contact_backup>
      <last_name>Research Coordinator2</last_name>
    </contact_backup>
    <investigator>
      <last_name>Joanne Billings, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator1</last_name>
    </contact>
    <contact_backup>
      <last_name>Research Coordinator2</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dave Young, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2012</study_first_posted>
  <last_update_submitted>December 8, 2014</last_update_submitted>
  <last_update_submitted_qc>December 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney safety</keyword>
  <keyword>biomarkers</keyword>
  <keyword>serum creatinine</keyword>
  <keyword>BUN</keyword>
  <keyword>cystic fibrosis</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>renal injury</keyword>
  <keyword>drug induced acute kidney injury</keyword>
  <keyword>aminoglycoside</keyword>
  <keyword>cisplatin</keyword>
  <keyword>nephrotoxicity</keyword>
  <keyword>biomarker qualification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

